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Microtubule-associated protein tau aggregates constitute the characteristic neuropathological features of several
neurodegenerative diseases grouped under the name of tauopathies. It is now clear that the process of tau
aggregation is associated with neurodegeneration. Several transgenic tau mouse models have been developed where
tau progressively aggregates, causing neuronal death. Previously we have shown that transplantation of astrocytes in
P301S tau transgenic mice rescues cortical neuron death, implying that the endogenous astrocytes are deficient in
survival support. We now show that the gliosis markers Glial fibrillary acidic protein (GFAP) and S100 calcium-binding
protein B (S100β) are elevated in brains from P301S tau mice compared to control C57Bl/6 mice whereas the
expression of proteins involved in glutamine/glutamate metabolism are reduced, pointing to a functional deficit. To
test whether astrocytes from P301S mice are intrinsically deficient, we co-cultured astrocytes and neurons from control
and P301S mice. Significantly more C57-derived and P301S-derived neurons survived when cells were cultured with
C57-derived astrocytes or astrocyte conditioned medium (C57ACM) than with P301S-derived astrocytes or astrocyte
conditioned medium (P301SACM), or ACM from P301L tau mice, where the transgene is also specifically expressed in
neurons. The astrocytic alterations developed in mice during the first postnatal week of life. In addition, P301SACM
significantly decreased presynaptic (synaptophysin, SNP) and postsynaptic (postsynaptic density protein 95, PSD95)
protein expression in cortical neuron cultures whereas C57ACM enhanced these markers. Since thrombospondin 1
(TSP-1) is a major survival and synaptogenic factor, we examined whether TSP-1 is deficient in P301S mouse brains and
ACM. Significantly less TSP-1 was expressed in the brains of P301S tau mice or produced by P301S-derived astrocytes,
whereas supplementation of P301SACM with TSP-1 increased its neurosupportive capacity. Our results demonstrate
that P301S-derived astrocytes acquire an early functional deficiency that may explain in part the loss of cortical neurons
in the P301S tau mice.
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Several neurodegenerative diseases, such as Alzheimer’s
disease (AD), progressive supranuclear palsy (PSP),
corticobasal degeneration (CBD), Pick’s disease (PiD),
argyrophilic grain disease, and inherited frontotemporal
dementia and parkinsonism linked to chromosome 17
(FTDP-17T) are characterized by the presence of* Correspondence: mgs11@cam.ac.uk
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consist of hyperphosphorylated microtubule-associated
protein tau and are collectively designated as tauopa-
thies [18, 26, 43]. The identification of mutations in the
MAPT gene in FTDP-17T [22, 43, 44] has established
that dysfunction or misregulation of the tau protein is
central to the neurodegenerative process in disorders
with tau pathology. Furthermore, in AD it is the ac-
cumulation and dysfunction of tau that causes cell
death and best correlates with the appearance of
dementia [7, 18].le is distributed under the terms of the Creative Commons Attribution 4.0
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hyperphosphorylated tau is critical for development of
disease and neuronal death [15, 36], the mechanism of
tau-related toxicity is still not clear. P301S tau transgenic
mice (P301S mice) expressing human tau under the con-
trol of the neuronal Thy1.2 promoter develop neuronal
tau aggregates in many brain areas [1]. Tau pathology de-
velops stereotypically between 2 and 5 months of age cul-
minating in neuronal death most notably observed in the
superficial layers of the motor and, perirhinal and piriform
cortices [1, 9, 51, 52]. To determine whether altering the
environment can extend neuronal survival, we trans-
planted neuron precursor cell (NPC)-derived astrocytes
and showed that neuronal death in the superficial layers of
the motor cortex was prevented [19], indicating a defi-
ciency in survival support, or a gain of toxic functions, by
the endogenous astrocytes. Astrocyte activation and react-
ive gliosis are associated with disease progression in al-
most all human neurodegenerative diseases [33, 48] and
astrogliosis appears to precede neuronal loss, suggesting
an important causative role of astrocytes in the develop-
ment of disease [27].
Here we investigate the reasons why astrocytes from
P301S mice do not prevent neuronal death whereas trans-
planted control astrocytes do. We show that astrocytes
derived from the superficial cortex of P301S mice exhibit
changes in cell specific markers that indicate astrocyte
dysfunction. Moreover we demonstrate in in vitro systems
that astrocytes or astrocyte conditioned medium from
wild type mice have neuroprotective and synaptogenic
functions that are absent in astrocytes from P301S- or
P301L-tau expressing mice, which can be attributed in
part to a reduction in thrombospondin-1 (TSP-1) expres-
sion in conditioned medium from P301S astrocytes.
Overall, our data demonstrate that astrocytes in the
P301S tau mice are directly involved in neuronal death
even though they do not express tau, highlighting a
novel important contribution of astrocytes to tau-related
pathogenicity, opening up new therapeutic avenues for
treating diseases with tau pathology.
Materials and methods
Animals
Neurons and astrocytes were prepared from postnatal
day 1–2, or 7–9 P301S tau or P301L tau female and
male mice [1, 45] along with age-matched C57BL/6 con-
trol mice. The tau mutation in the P301S mice is in the
human 0N4R isoform whereas in the P301L mice, it is
in the 2N4R isoform. Brain extracts were prepared from
3 to 5 month-old P301S and C57BL/6 mice. This re-
search was conducted under the Animals (Scientific Pro-
cedures) Act 1986, Amendment Regulations 2012,
following ethical review by the University of Cambridge
Animal Welfare and Ethical Review Body (AWERB).Brain extracts
Mice were killed by cervical dislocation and brains were
snap frozen on dry ice. Thick coronal slices (100 μm) ex-
tending from approximately 2.2 mm rostral to the
bregma to the bregma were cut using a cryostat. The
upper layers of the sensorimotor cortex were specifically
dissected out using an ophthalmic blade. Dissected brain
tissues were stored at −80 °C until use.
Astrocyte cultures
Primary astrocyte cultures were prepared from the cerebral
cortex of 1–2 or 7–9 day-old C57 and P301S mice,
or 7–8 day-old P301L mice as described previously [42].
Briefly, mice were decapitated, the cortex was isolated and
was triturated in HBSS (Hanks’ Balanced Salt Solution) by
pipetting up and down. The cell suspension was incubated
in 0.05% trypsin in HBSS at 37•C to further dissociate the
cells. After 30 min, fetal bovine serum (FBS) was added to a
final concentration of 5% and the cell suspension was centri-
fuged at 1200 rpm. Pelleted cells were resuspended in
DMEM with Earle’s salts supplemented with 10% FBS,
100 units/mL of penicillin and 100 μg/mL of streptomycin
and plated in non-coated T75 flasks (ThermoScientific) at a
density of 105 cells/ml. The cultures were maintained at
37 °C in 5% CO2. Twenty-four hours after the initial plating,
the medium was changed to remove non-adherent cells.
When cultures reached confluence (about 1 week), non-
astrocytic cells were separated from astrocytes by shaking
for 15 h at 50 rpm at 37 °C (Luckham R300). Astrocyte-
enriched cultures were then passaged into PDL-coated plates
and maintained under the same conditions as the initial cul-
tures. The surface-adherent monolayer cultures were > 98%
positive for the astrocytic marker glial fibrillary acidic protein
(GFAP). Cells were used for experiments after 5–6 days.
Neuronal cultures
Primary neuronal cultures were prepared from the
cerebral cortex (3 brains per preparation) of ≥7 day-old
or 1–2 day-old C57 and P301S mice. Briefly, neurons
were isolated following the same protocol used for astro-
cytes and cultured in Neurobasal medium supplemented
with 5% heat-inactivated bovine calf serum (Hyclone),
B27, 1 mM L-glutamine, 100 U/mL of penicillin and
0.1 mg/mL streptomycin. Neurons were plated at a dens-
ity of 105 cells/ml on 35 mm dishes coated with poly-D-
lysine (10 μg/ml; Sigma). Cytosine arabinoside (2.5 μM)
was added to the cultures on the second day after seeding
to inhibit the proliferation of non-neuronal cells. Cells
were used for experiments after 5–6 days. This protocol
produced a neuron-enriched culture (95% of neurons).
Direct neuron–astrocyte co-cultures
Primary purified astrocytes from the second passage
were plated at a density of 1.7 × 104 cells/cm2 on the top
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ture for 5–7 days. Co-cultures were fed with a mixture
of one-third of astrocytic and two-thirds of neuronal
medium, maintained at 37 °C in a humidified atmos-
phere of 5% CO2 and analyzed 4 and 8 days later. Cells
were fixed and stained with the neuronal marker β-III-
tubulin and the astrocytic marker GFAP to determine
neuron/astrocyte number. Several fields per each experi-
mental condition were scored for presence of neurons
and astrocytes as described in the figure legends and the
total number counted was used as a single value for stat-
istical purposes. Results were obtained from 3 to 4 inde-
pendent experiments (cell cultures) and each culture
contained cells from the cortex of three mice.
Astrocyte conditioned medium (ACM)
Pure astrocyte cultures grown as described above for
5–6 days were passaged once. After reaching conflu-
ence, cultures were thoroughly washed to eliminate re-
sidual serum, and the cultures were maintained without
fetal bovine serum for 1 day. The medium was then
collected and centrifuged to remove cellular debris at
1000 rpm for 5 min and used immediately. To analyse
the effect of ACM on neuronal survival, the medium in
which the neurons were grown for 5–7 days was re-
placed with ACM and survival was analyzed after 4 and
8 days by counting β-III-tubulin positive neurons.
TSP-1 withdrawal or supplementation to ACM
TSP-1 was depleted from C57ACM by immunoprecipi-
tation with an anti-TSP-1 antibody (Abcam, ab140250,
1:500) using magnetic Protein G Dynabeads (Invitrogen).
Briefly, anti-TSP-1 antibody (Abcam 140250, 1:500) was
incubated with Dynabeads with rotation for 10 min at
room temperature. Then, C57ACM was added to the
Dynabead-Ab complex, rotated for 10 min at room
temperature, and immune complexes bound to the
beads were pelleted by applying a magnetic field. The
TSP-1-depleted ACM supernatant was collected and ap-
plied to neurons for 4 days. TSP-1 removal was verified
by immunoblotting. For TSP-1 supplementation, ACM
from P301SA was enriched with recombinant mouse
TSP-1 (rTSP-1, 500 ng/ml, NovusBio) and the mixtures
were added to cultured neurons for 4 days. Neuronal
survival was determined by counting neurons identified
by immunocytochemistry with anti-β-III-tubulin.
Proliferation capacity
Astrocytes grown to 98% confluence, were repassaged
and analyzed after 2 days. Cells were incubated with the
thymidine analogue 5-ethynyl-2′-deoxyuridine (EdU,
10 μM final concentration, ThermoScientific) for 2 h at
37 °C, fixed and stained using the Click-iT® EdU Alexa
488 Cell Proliferation kit (ThermoScientific).Western blot analysis
Tissue, cultured astrocytes or neurons were lysed in
RIPA buffer (150 mM NaCl, 1.0% IGEPAL® CA-630,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
and 50 mM Tris, pH 8.0) containing protease and phos-
phatase inhibitor cocktails (Sigma). Tissue was left in
RIPA buffer for 20 min on ice before homogenisation
with a teflon pestle. Homogenates were spun at 13,000 ×
g for 30 min and the supernatants were used for ana-
lysis. ACMs were concentrated by spinning at 3750 × g
for 25 min in an Amicon centrifuge filter tubes with a
10 kDa molecular weight cut-off. Protein concentrations
in the tissue extracts, cell lysates or ACM were deter-
mined with the bicinchoninic acid (BCA) protein assay
kit (Pierce, ThermoScientific). An equal amount of pro-
tein from cells or ACM (15 μg) was loaded and run on a
12% SDS-PAGE and then transferred to a polyvinylide-
nefluoride membrane (EMDMillipore). Non specific
background was blocked by a 1 h incubation at room
temperature in 5% non-fat dry milk in Tris Buffered Sa-
line with 0.1% Tween 20 (TBS-T). Incubations with pri-
mary antibodies were carried out at 4 °C for 24 h in 5%
non-fat milk in TBS-T buffer at the following antibody
concentrations: anti-GLAST (Abcam, ab416, 1:1000),
anti-GLT1 (Abcam, ab41621, 1:1000), anti-GS (Abcam,
ab49873, 1:2000), anti-GFAP (Abcam, ab10062, 1:2000),
anti-S100β (Abcam, ab14688, 1:1000), anti-TSP-1 (Abcam,
ab85762, 1:1000), anti-PSD-95 (Abcam, ab18258, 1:2000),
anti-synaptophysin (SNP) (Abcam, ab106618, 1:1000),
anti-beta actin (Sigma, A2066, 1:5000). Secondary anti-
body incubations were performed at room temperature
for 1.5 h using HRP-conjugated anti-rabbit IgG (Thermo-
Scientific, 1:2000) or anti-mouse IgG (Sigma, 1:4000).
For ACMs, blots were visualized with Ponceau S
(Sigma) and developed with Supersignal West Dura
Extended Duration Chemiluminescent Substrate (Pierce,
ThermoScientific).
Immunocytochemistry
Primary neuronal, astrocytes or astrocytic-neuronal co-
cultures plated on glass coverslips were washed twice
with TBS and fixed at room temperature for 10 min with
100% cold methanol. Cells were permeabilized with 0.1%
Triton X-100 in PBS for 15 min and then incubated for
1 h in 5% goat serum to reduce nonspecific background.
After an overnight incubation at 4 °C with the primary
antibodies: [chicken or mouse anti-glial fibrillary acidic
protein (Abcam, ab4674, 1: 200 or Dako, z0334, 1:500),
anti-β-III-tubulin, (Abcam, ab18207, 1:500 or Covance,
MMS-435P 1:1000), anti-synaptophysin (Abcam, ab106618,
1:500), anti-NeuN (Millipore, MAB377, 1:500)], cells
were washed with TBS and incubated with secondary
AlexaFluor-conjugated antibodies appropriate for the
species (Molecular Probes, 1:500). To visualize cell
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4′,6-diamidino-2-phenylindole dihydrochloride hydrate
(DAPI)/antifade (Sigma, 1:1000) diluted in TBS or
Hoescht dye (Sigma, 1:5000) for 10 min at room
temperature. Cover slips were mounted in FluorSave™
(EMD Millipore) and pictures were taken with a wide-
field fluorescence microscope (Leica DMI 4000B micro-
scope using a Leica DFC3000 G camera and the Leica
application suite 4.0.0.11706).
Image analysis
Western blot and SNP intensity analyses were carried out
using ImageJ (Rasband, W.S., ImageJ, U.S. National
Institutes of Health, http://imagej.nih.gov/ij/, 1997–2014).
Quantification of SNP expression in neurons was per-
formed by measuring mean fluorescence staining intensity
within the contour drawn around the individual cells in
SNP-stained neuronal cultures. At least six cells per field,
and four fields per technical replicate were analyzed.
Bands on blots were quantified by measuring mean gray
value of individual bands using the Measure tool in ImageJ
or the AlphaEaseFC Imaging System software (Alpha
Innotech).
Statistical analysis
Data are expressed as mean ± SEM. Results from tech-
nical replicates or from counting several fields in each
culture were pooled to give a single value for statistical
purposes. Statistical analyses for significant differences
were performed with unpaired t test, or one- or two-way
ANOVA followed by Tukey’s posthoc test or Mann-
Whitney where appropriate, using GraphPad Prism 5.0
software. The criterion for statistical significance was
p < 0.05.
Results
Astrocytes from P301S mice exhibit loss of functional
proteins and gain of gliosis markers
To examine whether astrocytes had altered phenotypes
in P301S mice at early and late stages of tau pathology,
extracts from the superficial layers of the cortex of 3
and 5 month-old C57 control and P301S mice were
analysed by immunoblotting. Figure 1a–c shows that
lysates from P301S mice expressed higher amounts of
GFAP already at 3 months of age (~3 fold), which
persisted up to 5 months of age, whereas S100β
expression was elevated (~2 fold in the sample from
5 month-old mice, indicating astrogliosis. In contrast
(Fig. 1d–g), there was a reduction in the expression of
proteins involved in key astrocytic neurosupportive
functions relating to glutamine/glutamate metabolism
[35], including GS (glutamine synthetase, 2 fold at
3 months (m) and 1.8 fold at 5 m); GLAST (the GLu-
tamate ASpartate Transporter also known as EAAT1or SLC1A3; 2 fold at 3 m and 1.5 fold at 5 m); GLT1
(glial glutamate transporter also known as EAAT2 or
SLC1A2; 1.8 fold at 3 m). To determine whether astro-
cytes from P301S tau mice recapitulate these abnormal
phenotypes in vitro, we examined the expression of the
same proteins in astrocyte cultures derived from the
cerebral cortices of 7–8 day-old C57 (control; C57A)
or P301S tau (P301SA) mice. Astrocytes were grown to
confluence, shaken to remove non-adherent cells, and
re-plated to generate 98% pure astrocytic cultures be-
fore protein extraction. Similar to the results obtained
from the brains, GFAP protein expression was signifi-
cantly elevated, while those of GS, and GLT1 were
significantly decreased in lysates from P301SA com-
pared to C57A (Fig. 1h, i). These results show that
both cultured and endogenous astrocytes from P301S
tau mice possess an abnormal phenotype from an early
postnatal age that is retained in adulthood.P301S astrocytes show an increased proliferation
capacity
Astrocyte proliferation is a prominent cellular response
to diverse brain pathologies, which induce heteroge-
neous and progressive changes in astrocyte gene expres-
sion and cell function. Having observed significant
increases in expression of GFAP in P301SA, we exam-
ined the proliferation of the cultured astrocytes over
24 h by incorporating the alkyne-modified thymidine
analogue EdU into the DNA of dividing cells followed
by labelling with AlexaFluor488 using click chemistry.
Consistent with the observed increase in GFAP, there
was a significant increase in the rate of proliferation of
P301SA compared to control C57A (Fig. 2a, b).Effect of astrocyte-neuron co-cultures on neuronal
survival
To determine whether the neuroprotective/neurotoxic
effects of C57A/P301SA observed in P301S tau trans-
genic mice was recapitulated in vitro, we established
primary co-cultures of astrocytes with cortical neurons
obtained from at least 7 day-old pups, a stage at which
there is consistent neuronal transgenic tau expression
and initial signs of behavioural dysfunction in the
P301S mice [40]. Counting the number of neurons
after 4 or 8 days using anti-β-III-tubulin, and astro-
cytes using anti-GFAP (representative images shown in
Fig. 3a), showed that there were significantly higher
numbers of neurons cultured from C57 mice (C57N)
or P301S tau mice (P301SN) when cells were co-
cultured with C57A than with P301SA, especially not-
able after 8 days in culture (Fig. 3b, c). The number of
astrocytes instead remained similar in all co-culture
combinations (Fig. 3d, e).
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Fig. 1 Astrocytes from P301S mice express more GFAP and S100β and less GS, GLT-1 and GLAST than astrocytes from control mice. a, d Representative
blots of astrocyte-specific protein markers related to gliosis/proliferation (GFAP, S100β) and function (glutamine synthetase (GS) and the glutamate
transporters (GLT-1 and GLAST)) in the superficial motor cortex of 3 month-old and 5 month-old C57 and P301S mice. h Expression of the same markers
in primary pure cultured astrocytes from 7 day-old mice after days 8 in vitro (98% culture confluence). Mean ± SEM, *p < 0.05 vs control; unpaired t test,
N= 3 independent experiments (mice: GFAP, S100β (b, c); GLT-1, GLAST, GS (e–g); primary cultures i). Vertical lines in (d) denote point were the picture
of the Western blot was assembled from two parts cut from the same blot
Sidoryk-Wegrzynowicz et al. Acta Neuropathologica Communications  (2017) 5:89 Page 5 of 15Conditioned medium from C57A and P301SA cultures
replicate the effects of the respective astrocytes on
neuron survival
To determine whether the effect of the astrocytes on
neuron survival requires constant neuron-astrocyte
contact or consists of soluble factors released by the
astrocytes, we cultured C57N and P301SN in astrocyte-
conditioned medium (ACM) from C57 (C57ACM) or
P301S (P301SACM) mice. ACMs were collected after
24 h from pure astrocyte cultures that were washed and
maintained in serum-free medium. Figure 4a shows rep-
resentative images of the various cultures while Fig. 4bshows that the number of surviving C57N and P301SN
was significantly higher when cells were cultured with
C57ACM compared to P301SACM, suggesting that
C57-derived but not P301S-derived astrocytes support
neuronal survival by releasing soluble factors. To ex-
clude the possibility that the lack of survival support by
P301SA is specific to the P301S tau mouse model, we
generated ACM from astrocytes derived from P301L
transgenic mice expressing human 2N4R tau in neurons
under the Thy1.2 specific neuronal promoter [45]. These
mice were chosen because the transgene is expressed
under the same Thy1.2 promoter used to generate the
ab
Fig. 2 Astrocytes from P301S mice are more proliferative. Proliferation assay using EdU was performed 1 day after passage of confluent astrocyte
cultures from 7 day-old pups. A higher proliferation capacity was observed in P301SA compared to C57A astrocytes. a Representative images
where red indicates nuclei undergoing proliferation. b Quantification of proliferating cells, mean ± SEM, *p < 0.05 vs control; statistical analysis was
performed using unpaired t test. N = 3 independent experiments where counting from three technical replicates (wells) in which at least three
fields per well were analyzed constitute one value for statistical purposes. EdU, 5-ethynyl-2'-deoxyuridine
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expression in astrocytes, which could confound the results
(see Additional file 1: Figure S1 for evidence that no tau
transgene is expressed in astrocytes in P301S tau brains or
in astrocyte extracts cultured from P301S or P301L mice).
Figure 4c shows that addition of P301LACM also failed to
enhance neuron survival, showing that the lack of survival
support by P301SA is not related to the insertion site of the
transgene in the mouse genome, and can be generalized to
include another transgenic model of tau pathology.
Although neither transgenic tau nor endogenous tau is
expressed in astrocytes in the P301S/L mice, we asked
whether there is an age dependent component to the ac-
quisition of astrocyte dysfunction. The earliest signs of
tau-induced abnormalities appear in the P301S tau mice
around 3 days postnatally [40]. We therefore examined
whether ACM obtained from astrocytes from 1 to 2 day
old mice would have the same effect on neurons from
either 1–2 day - or 7 day-old pups. Figure 4d shows that
there were no differences in neuronal survival over 4 days
when C57N or P301SN from 1 to 2 day-old mice were
exposed to C57ACM or P301SACM that were grown
from 1 to 2 day-old mice, suggesting that astrocytes ac-
quire differential properties once pathological tau begins
to be consistently present in the neurons. Moreover,
neuron survival was not differentially affected after ex-
posure of neurons derived from 7 day-old mice to ACMsfrom 1 to 2 day-old mice (Fig. 4e), indicating that the lack
of response to ACM from 7 day-old mice in Fig. 4d was
not due to the neurons being cultured from young mice.
These data indicate that a certain amount of transgenic
tau in young neurons is required to alter the propensity of
astrocytes to support the neurons.
P301SACM fails to support the development of synaptic
protein expression
Recent evidence suggests that astrocytes mediate neuro-
protection by releasing factors that regulate synapse
formation and integrity (for example, [46]). To address
whether synaptic development is differentially affected by
the two types of astrocytes, C57N and P301SN from
7 day-old pups were grown with C57ACM or P301SACM
for 8 days, after which the expression of the presynaptic
protein synaptophysin (SNP) and the postsynaptic protein
PSD-95 were examined by immunoblotting. P301SACM
significantly inhibited the expression of SNP in both
C57N and P301SN and also inhibited the expression of
PSD-95 in C57N (Fig. 5a–c) whereas C57ACM main-
tained robust SNP and PSD-95 expression, and even in-
creased expression of PSD-95 in P301SN, where basal
expression was low. This 3–4-fold reduction was not due
to neuronal cell death because the percentage of death in
cultures treated with P301SACM did not exceed 10%. To-
gether our results suggest that ACM from C57 mice has
ab c
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Fig. 3 Astrocytes from P301S mice have a reduced capacity to support neuronal survival. Primary astrocytes (C57A and P301SA) cultured from cerebral
cortex of 7 day-old mice (98% purity) were plated on top of primary neurons cultured from mice of similar age and brain region for 4–5 days.
Co-cultures were maintained for 4 and 8 days. a Representative images of co-cultures immunostained for β-III-tubulin (red), GFAP (green) and Dapi (blue).
Quantification of neuron (b, c) and astrocyte (d, e) numbers after 4 and 8 days of co-culture. Each experiment consisted of six technical replicates (wells)
in which at least five fields were analyzed. Data show mean per field ± SEM from at least four independent experiments. Data were analysed using
ANOVA followed by Tukey’s multiple comparison test; *p < 0.05 for these comparisons: C57N vs C57N + P301SA; C57N vs P301SN + P301SA; C57N vs
C57N + C57A; C57N + C57A vs P301SN + C57A; C57N + C57A vs C57N + P301SA; C57N + C57A vs P301SN + P301SA; P301SN + C57A vs P301SN +
P301SA; ANOVA of results from 4 day co-cultures revealed a significant interaction between genotype and co-culture condition [F (2, 21) = 4.477;
p = 0.0240], significant effects of co-culture type [F (2, 21) = 14.27; p = 0.0001] and genotype [F (1, 21) = 14.8; p = 0.0009]. In 8 day of co-cultures,
ANOVA revealed no interaction between genotype and culture conditions [F (2, 22) = 3.048; p = 0.0678], the significant effect being co-culture type
[F (2, 22) = 17.51; p < 0.0001] and co-culture condition [F (1, 22) = 6.54; p = 0.0180]. No significant differences in the numbers of astrocytes were present
between the various cultures
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from P301S mice older than 7 days has negative effects.
Astrocyte protein secretome characterization
Astrocytes secrete a huge variety of factors including
proteins, chemokines, cytokines as well as small metabo-
lites such as nucleosides and nucleotides. Proteins can besecreted as individual proteins or within various types of
vesicles, such as exosomes. Free proteins may include
extracellular matrix components as well as, growth factors,
chemokines and cytokines, whereas vesicles can contain
membrane proteins as well as RNA [25, 47]. To examine
whether macromolecules or small metabolites secreted by
astrocytes are responsible for the neuroprotective and
a b
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Fig. 4 Astrocytes from P301S and P301L tau mice develop a reduced capacity to support neuronal survival during the first postnatal week. Serum-free
medium conditioned by pure astrocytes derived from ≥7 day-old C57, P301S and P301L tau mice over 24 h was centrifuged to remove cellular debris
and immediately added to 7 day cultured neurons extracted from 7 day-old mice. After 8 days, cells were fixed, stained with β-III-tubulin and counted.
Mean ± SEM of four independent experiments where a single value is from four technical replicates (wells) in which at least five fields per well were
analyzed. a Images of neurons treated with the various ACMs as indicated. b ACM from 7 day-old C57 and P301S mice; *p < 0.05 for these comparisons:
no ACM C57N vs C57N + C57ACM; no ACM P301SN vs C57N + C57ACM; C57N + C57ACM vs P301SN + C57ACM, C57N + C57ACM vs C57N + P301SACM,
C57N + C57ACM vs P301SN + P301SACM, P301SN + C57ACM vs P301SN + P301SACM. c ACM from 7 day-old C57A and P301LA; *p < 0.05 for these
comparisons: no ACM C57N vs C57N + C57ACM; C57N + C57ACM vs C57N + P301LACM; Tukey’s multiple comparisons test. For 8 day of cultures,
ANOVA revealed no interaction between genotype and culture conditions [F (2, 18) = 1.174; p = 0.3317], significant effect of culture condition
[F (2, 18) = 19.73; p = 0.0001] and significant effect of genotype [F (1, 18) = 8.725; p = 0.0085]. d Neurons from 1 to 2 day-old mice were cultured for
4 days after which ACM derived from astrocytes cultured from 1 to 2 day-old mice was added for 4 days. e Neurons from 7 day-old mice were
cultured for 4 days after which ACM derived from astrocytes cultured from 1 to 2 day-old mice was added for 4 days. Note that in both cases, there is
no difference between the effects of ACMs from C57 or P301S mice. Mean ± SEM from three independent experiments; each value was obtained
from four technical replicates (wells) in which at least five fields were examined. Values were analysed by the Mann–Whitney test
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Amicon cellulose membranes with a 10 kDa molecular
weight cutoff. The retained fraction includes proteins and
compounds larger than 10 kDa whereas smaller proteinsand metabolites are filtered through. Neurons were treated
with the solute retained in the filter unit (bigger than
10 kDa, labelled ≥10 kDa) or with the filtered fraction
(smaller than 10 kDa, labelled ≤10 kDa). Figure 6 shows
ab c
Fig. 5 ACM from P301SA reduces synaptic protein expression in cultured neurons. C57N or P301SN cultures were exposed to C57ACM or
P301SACM for 8 days after which cell lysates were analysed by immunoblotting. a Representative immunoblot of synaptophysin (SNP) and PSD95
in neuronal cultures with and without ACM exposure. Note the significant decline of both (b) SNP and (c) PSD95 when C57N or P301SN were
cultured with P301SACM compared to neurons maintained in C57ACM. Data were normalised to β actin and represent mean ± SEM of three
independent experiments performed in triplicate. *p < 0.05 for these comparisons: C57N vs C57N + P301SACM; C57N + P301SACM vs
C57N + C57ACM; P301SN vs P301SN + P301SACM; P301SN vs P301SN + C57ACM; Tukey’s multiple comparisons test both for SNP and PSD95.
ANOVA for SNP values revealed a significant interaction between genotype and culture condition [F (2, 12) = 29.88; p = 0.0001], significant effect
of genotype [F (1, 12) = 307.2; p = 0.0001] and significant effect of culture treatment [F (2, 12) = 34.68; p = 0.0001]. ANOVA for PSD95 values
revealed a significant interaction between genotype and culture condition (ACM) [F (2, 12) = 18.08; p = 0.0002], significant effect of genotype
[F (1, 12) = 112.2; p = 0.0001] and culture treatments [F (2, 12) = 37.01; p = 0.0001]
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ever, higher numbers of C57 and P301S neurons, compar-
able to the numbers observed with the full C57ACM,
were obtained when cells were cultured with the
C57ACM ≥10 kDa fraction (diluted to the original volume
to ensure that the effect is not due to the higher concen-
tration of ACM components in the retained fraction), in-
dicating that astrocyte-derived factor(s) supporting
neuronal survival in case of C57A are macromolecule(s)
rather than small metabolites.
Thrombospondin 1 involvement in astrocyte-dependent
neuroprotection and neurodegeneration
In a preliminary analysis of the proteome of C57ACM
and P301SACM, we noted that thrombospondin 1 (TSP-
1), a protein heavier than a 10 kDa molecular weight,
was reduced in P301SACM compared to C57ACM by
about 50%. TSP-1 is an astrocyte-derived regulator of
synaptogenesis important for synaptic recovery from
brain injury [28] as well as neuron survival [46], and its
secretion was impaired in an in vitro amyloid model of
Alzheimer’s disease [37]. We therefore examinedwhether TSP-1 may contribute to the effect on the ex-
pression of synaptic markers that we observed following
exposure of the neurons to ACM. Figure 7a, c shows
that cortical extracts from 3- to 5 month -old P301S tau
mice contained 30–40% of the amount of TSP-1 present
in the control C57 brain extracts. Similarly, the amount
of TSP-1 in astrocytes from 8 day-old mice cultured for
3 weeks was significantly reduced by 50% in P301SA
compared to C57A (Fig. 7b, c). C57A released higher
amount of TSP-1 than P301SA (Fig. 7d). Furthermore,
C57 astrocytes secreted significantly higher amounts of
TSP-1 than C57 neurons (Fig. 7e) and this difference in
the amount of TSP-1 was also found when ACMs were
added to neurons for 24 h (Fig. 7f ).
To examine whether TSP-1 is implicated in the sur-
vival and synaptogenesis of the C57ACM, TSP-1 was
immuno-depleted from the C57ACM and the depleted
ACM was added to neuronal cultures. Exposure to TSP-
1-depleted ACM caused a decline in SNP immunoractiv-
ity in both C57N and P301SN (Fig. 8a–c), suggesting
that the reduced amount of TSP-1 in the ACM might
explain at least in part the loss of synaptic development
Fig. 6 The active components in C57ACM are macromolecules with
a MW above 10 kDa. C57N and P301SN cultures were exposed to
complete C57ACM and the same ACM fractionated through a filter
with a cut off of ≥10 kDa. The fraction ≥10 kDa (which was diluted
to the original volume to offset changes due to concentrating the
ACM) or ≤10 kDa was added to the neurons for 8 days. Neurons were
counted after immunostaining with the neuronal marker β-III-tubulin.
*p < 0.05 for comparisons between number of neurons in:
NB vs C57ACM; C57ACM vs C57ACM-10 kDa; C57ACM-10 kDa vs
C57ACM + 10 kDa; similar significance was found when C57N or
P301SN were treated, statistical analyses was done using Tukey’s
multiple comparisons test. ANOVA revealed no interaction on
genotype and culture condition (ACM) [F (3, 22 = 0.1457; p = 0.9314],
no effect for genotype [F (1, 22) = 0.03553; p = 0.8522] but a significant
effect of culture type (ACM) [F (3, 22) = 30.6; p = 0.0001]. The data
represent a mean of at least three independent experiments. Each
experiment consisted of four technical replicates (wells) in which at
least three fields were analyzed
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TSP-1 from C57ACM and P301SACM reduced the sur-
vival of both C57N and P301SN (Fig. 9a, b). Conversely,
the addition of 500 ng recombinant TSP-1 to the
P301SACM was sufficient to restore neuronal survival to
the levels observed with C57ACM (Fig. 9c, d), suggesting
that the reduction in TSP-1 expression in P301SACM
may play an important role in the loss of neuronal
survival in the P301S transgenic mouse.Discussion
Transgenic human P301S tau mice, where tau is
expressed specifically in neurons under the control of
the Thy1 promoter [1], display progressive tau aggrega-
tion and neuron loss with associated astrogliosis in the
superficial layers of the cerebral cortex between 2 and
5 month of age [19]. We have previously shown that this
neuronal death can be rescued by transplantation of
neuronal precursor cell-derived astrocytes from wild
type mice [19], implying that the endogenous astrocytes
are functionally deficient in P301S tau mice. To deter-
mine why transplanted astrocytes were protective we
prepared primary co-cultures of postnatal astrocytes and
neurons from the cortex of P301S tau transgenic and
control mice. Our findings demonstrate that endogenous
astrocytes from P301S tau mice are deficient in factors
that wildtype astrocytes secrete in order to supportneuronal survival and synaptogenesis. Our results thus
explain the observation that wildtype astrocytes rescue
transgenic P301S tau cortical neurons from death by
showing that they express neurosupportive factors which
are lacking in P301S-derived astrocytes.
To understand the biochemical basis for these differ-
ences we examined the expression of key proteins impli-
cated in astrocyte function. We found an increase in the
expression of GFAP and S100β, astrocytic proteins re-
lated to glial responses to injury, both in extracts from
the cerebral cortex of 3 and 5 month-old P301S mice,
extending previous immunohistochemical findings [1,
19], and in primary cultures of astrocytes from P301S
tau mice. Correlated with this increase, we found that
cultured astrocytes from P301S mice showed enhanced
proliferative capacity relative to those from control mice,
indicating a cell autonomous memory of a previous
injury-like state. Although this does not signify whether
these changes are adaptive or maladaptive, they indicate
highly coordinated changes in astrocyte behaviour [3, 21].
Our immunoblot analyses also uncovered significant
changes in the expression of proteins related to glutamate
homeostasis in the superficial cerebral cortex of 3 and
5 month-old P301S tau mice and in primary cultures of
astrocytes. Astrocytes secrete glutamate in response to ac-
tivation, modulate glutamate receptor expression, and re-
move glutamate from the synaptic cleft by glutamate
transporters [2, 4, 49]. This regulation of synaptic glutam-
ate is crucial for normal CNS function, and the sodium-
dependent glutamate transport system located peri-
synaptically on astrocytes contributes to the regulation of
extracellular glutamate levels. Because astrocytes play a
major role in control of glutamate homeostasis, we fo-
cused on three important regulatory proteins of glutamate
metabolism, GS, the main glutamine metabolizing enzyme
[34], GLAST and GLT1 [12, 34, 38], the astroglial-specific
Na+/glutamate transporters. We found a reduced expres-
sion of all three proteins in extracts from the superficial
cortex of P301S mice, which were also evident in astro-
cytes cultured from these mice, despite their being ex-
panded for several days ex-vivo.
Decreases in the expression of GLAST and GLT1 were
previously reported in astrocytes expressing GFAP/tau
mice, wildtype tau or P301L mutant tau [14]. These mice
manifested motor deficits before the development of
overt tau pathology, which correlated with loss of ex-
pression and function of both glial glutamate trans-
porters. Interestingly, there was no difference in effect
between the mutant and non-mutant transgenic tau in
these mouse models and since tau is not normally
expressed in astrocytes, it is not clear how this pathology
related to tau toxicity elicited by neurons. Notably, these
models are different from our transgenic P301S mice
where tau (mRNA and protein) is expressed only in
a b
c d
e
f
Fig. 7 TSP-1 expression is reduced in the superficial cortex and in cultured astrocytes or ACM from P301S mice. a Lysates from the superficial
cortex of 3 and 5 month-old mice or b from astrocytes from 98% pure cultures from 7 day-old mice were analysed for TSP-1 expression by
immunoblotting. c Quantitative analysis of TSP-1 expression normalised to actin. Values for C57-derived controls are set to 1. *p < 0.05 for these
comparisons: C57 3 m vs P301S 3 m; C57 5 m vs P301S 5 mo; C57A vs P301SA. d Analysis of ACM from C57A or P301SA after fractionation on an
Amicon filter with a 10 kDa cutoff. A significant decrease in TSP-1 was observed in P301SACM compared to C57ACM, *p < 0.05; e Representative
blot, and f quantification of TSP-1.expression in C57ACM, pure C57 neuronal cultures (C57NCM), and C57 neurons co-cultured with C57ACM or
P301SACM. Ponceau S staining of ACM blot to show equal loading. *p < 0.05 for these comparisons: C57N + C57ACM vs C57N + P301SACM.
C57A released more TSP-1 than C57N, C57A vs C57N. The data represent a mean of three independent experiments performed in triplicates;
mean ± S.E.M, statistical analyses performed with Mann–Whitney test
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the changes in glutamate transporters in our system
must be related to neuron-astrocyte cross talk. In our
model, neuronal dysfunction drives the changes similar
to a reported mouse model of Parkinson’s disease where
disruption of striatal glutamatergic innervation resulted
in reduction in both GLT-1 and GLAST protein expres-
sion, accompanied by dysfunction of glutamate uptake
[16, 23, 31]. A study of a different P301S tau mouse
model (where P301S is expressed under the prion pro-
moter) revealed regional changes in glutamate levels that
correlated with histological measurements of pathology,
such as pathological tau, synapse and neuron loss [13].
Deficits in glutamate neurotransmission and mitochon-
drial dysfunction were also detected in the frontal cortex
and hippocampus of aged 3 × Tg AD mice, which develop
beta-amyloid plaques and tau aggregates containing
P301L tau [17]. Decreased expression of glutamate-metabolizing enzymes (such as glutamate dehydrogenase
and glutamine synthetase protein) in astrocytes were also
found in the cerebellum of patients with Alzheimer’s
disease [8]. In the 3xTg AD mice, wildtype astrocyte
transplantation was reported to improve altered behav-
iour and this improvement was attributed to increased
expression of BDNF [6] but we did not find a signifi-
cant increase in growth factors following transplant-
ation in our P301S tau mice [19]. A recent study has
shown that neuronal activity has a prime role in upreg-
ulating gene expression and function of glutamate
transporters in astrocytes [20]. Taken together, our re-
sults indicate that the glutamatergic system is one of
the vulnerable points in the reaction between astro-
cytes and neurons in brain disease and injury, where
astrocytes may fail to prevent glutamate excess and
neuronal toxicity through loss of proper glutamate
homeostasis.
ab
c
Fig. 8 TSP-1 depletion reduces the synaptogenic effects of C57ACM.
a TSP-1 was immunodepleted from crude C57ACM or from the
≥10 kDa fraction and depletion validated by immunoblotting. Blot
showsTSP-1 amounts in input, fraction bound to beads, and eluted
supernatant after magnetic separation. b Representative pictures of SNP
and NeuN immunocytochemistry. Complete ACM and TSP-1-depleted
ACM were added to the neuronal cultures for 8 days after which
cultures were fixed and immunolabelled with antibodies against SNP
and NeuN. c Quantification of SNP intensity. For quantification of
staining intensity of SNP in the green channel from three slides for each
experimental condition were analysed. Results indicate a mean which
corresponds in each case to the mean of four fields. *p< 0.05 for these
comparisons: C57N + C57ACM vs C57N + C57ACM-TSP-1;
P301SN + C57ACM vs P301SN + C57ACM-TSP-1. Values were analysed
using Tukey’s multiple comparisons test. ANOVA revealed no interaction
between genotype and culture condition (ACM or ACM-TSP-1)
[F (1, 12) = 0.9814; p= 0.3414] but a significant effect was found for
genotype [F (1, 12) = 62.94; P< 0.0001] while no effect for culture type
[F (1, 12) = 1.476; p = 0.2478]
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neurons, and P301SACM failed to protect neurons from
basal cell death whereas C57A or C57ACM enhanced
neuron survival. Notably, similar results were obtained
using ACM from astrocytes from P301L mice, where tau
is expressed under the same neuronal specific Thy1 pro-
moter as in our P301S mice [45]. Hence, the lack of sur-
vival support is not tau mouse model-specific nor is itrelated to a specific tau isoform or MAPT mutation or
due to the insertion site of the transgene in the mouse
genome but rather is due to the expression of mutant
tau and tau pathology development. Although tau fila-
ments and motor pathology develop consistently be-
tween 3 and 5 months in the P301S mouse, transgenic
tau is expressed from postnatal day 1 and significant
signs of altered behavioural function, detected by meas-
uring ultrasound vocalisation (USV) [39], are evident
already in newborn mice 3 days postnatal with increased
USV maintained up to 7 days [40]. Our findings indicate
that astrocytes develop pathological changes due to the
exposure to P301S tau-expressing neurons in 7–8 day-old
pups but not in 1–2 day-old mice, since we found no
difference in neuron survival when neurons were ex-
posed for 8 days to astrocytes or ACM prepared from 1
to -2 day-old P301S tau mice. Although transgenic tau
is present in neurons in 1–2 day-old pups, it is possible
that either it is not sufficient to induce the astrocytic
reaction or that this response takes several days to de-
velop. At both ages, in 1–2 day- or 7 day-old pups no
aggregated tau is visible in neurons, indicating that
toxic events precede tau filament formation. Hence the
development of astrocyte dysfunction appears to relate
to the earliest manifestations of neuronal tau toxicity.
Recently, IPSCs-derived astrocytes from Down syn-
drome (DS) patients were shown to be toxic to neurons
but in this case astrocytes, like neurons, bear a trisomy
of chromosome 21 [9] whereas MAPT is located on
chromosome 17. Similar to our findings, however, the
study revealed that DS astroglia exhibited a higher pro-
liferation rate, and expressed higher levels of S100β and
GFAP. Furthermore, DS astrocytes contributed to the re-
duction of neurogenesis of DS NPCs and to the induc-
tion of DS neuron death via failure to promote
maturation and synapse formation in these cells. Loss of
functional synapses is a major neuropathological feature
that is well defined in many AD and FTD mice models
[10, 32, 41]. In keeping with these results, we observed a
significant decline in expression of the synaptic markers
PSD95 and synaptophysin upon exposure of neurons to
P301SACM. In contrast, exposure to C57ACM en-
hanced both neuron survival and expression of the two
synaptic markers we investigated.
To determine the possible factors involved in astro-
cyte dysfunction, we sought proteins that are differen-
tially expressed in the ≥10 kDa fractions of the ACM
that may be associated with a neuroprotective effect,
and thereby focused on TSP-1. TSP-1 is a well defined
molecule expressed in postnatal and young adult ani-
mal brains and in human cortical astrocytes where it
has been shown to promote neuroprotection [5, 30, 54],
to increase the number of synapses [11, 24], as well as
to accelerate synaptogenesis [50]. Furthermore, TSP-1
a b
c d
Fig. 9 Effect of TSP-1 depletion of C57ACM or supplementation to P301SACM on neuronal survival. To study the effect of TSP-1 on neuronal survival
C57N and P301SN were cultured in (a, b) C57ACM or C57ACM depleted of TSP-1 or (c, d) P301SACM or P301SACM supplemented with TSP-1 for
8 days. a, c Neuronal cultures were fixed and immunolabelled with anti-β-III-tubulin antibody to determine neuronal number. The data represent a
mean of three independent experiments. Each experiment consisted of three technical replicates (wells) in which at least three fields were analyzed.
b *p < 0.05 for these comparisons: number of neurons in C57N + NB vs C57N + C57ACM; C57N + C57ACM vs C57N + C57ACM-TSP-1; C57N + NB vs
C57N + C57ACM-TSP-1; P301SN + C57ACM vs P301SN + C57ACM-TSP-1. d *p < 0.05 for these comparisons: number of neurons in C57N + NB vs
C57N + P301SACM; C57N + P301SACM vs C57N + P301SACM + TSP-1; P301SN + NB vs P301SN + P301SACM + TSP-1; P301SN + P301SACM vs
P301SN + P301SACM + TSP-1. Results were evaluated with Tukey’s multiple comparisons. For experiments where TSP-1 was depleted ANOVA revealed
significant interaction on genotype and culture condition (ACM) [F (2, 12) = 18.01; p = 0.0002], a significant effect for genotype [F (1, 12) = 22.87;
p = 0.0004] and significant effect of culture type (ACM) [F (2, 12) = 32.75; p = 0.0001]. For experiments where TSP-1 were added, ANOVA revealed
no difference between genotype and culture condition (ACM) [F (2, 12) = 2.524; p = 0.1217], a significant effect of the genotype
[F (1, 12) = 9.39; p = 0.0098] and significant effect of culture type (ACM) [F (2, 12) = 32.75; p = 0.0001]
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that addition of amyloid-β peptides, the main compo-
nents of the amyloid plaques found in the brains of
Alzheimer’s patients, caused a significant decline in the
release of TSP-1 from primary cultures of astrocytes
[37]. We found that P301S astrocytes in vivo and
in vitro produce, and, in vitro, release significantly less
TSP-1. A similar decline of TSP-1 expression was de-
scribed in Down Syndrome astroglia pathogenesis [9].
To demonstrate that TSP-1 is a limiting factor in the
P301SACM, immune depletion of TSP-1 from C57ACM
significantly reduced neuronal survival of C57N and
P301SN, whereas supplementation of TSP-1 to P301SACM
restored viability, especially that of P301SN. Although we
focused on TSP-1, a preliminary analysis of ACMs indicatesthat it is unlikely that TSP-1 is the only factor that is limit-
ing in P301SACM. A proteomic study of adult symptom-
atic prion promoter-driven P301S mouse brains identified
some differentially expressed proteins in astrocytes, which
they propose to have neuroprotective functions [53].
However, the prion promoter may drive expression of tau
in astrocytes [29] whereas in our model no tau is
expressed in astrocytes. A key question that remains
is to find out why and how the expression of these
proteins is differentially regulated through neuron-
astrocyte interactions.
Conclusion
The present study reports that C57ACM exhibits neur-
onal pro-survival properties whereas P301SACM failed to
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neuronal support by ACM were observed in an independ-
ent P301L mouse model, where tau is expressed under the
same neuronal specific Thy1 promoter, indicating that our
results can be generalized as being a result of tau path-
ology. This effect of neuronal transgenic tau on endogen-
ous mouse astrocytes develops during the first week of life
in the brain of P301S and P301L mice, given that the lack
of neuronal support observed in astrocytes from 7 day-old
pups is not present in astrocytes from 1 to 2 day-old mice.
Although transgenic tau is present in 1–2 day-old pups ei-
ther its amount is not sufficient to induce the astrocytic
reaction or this can take some days to develop. At both
ages, in 1–2 day or 7 day-old pups no filamentous aggre-
gated tau is visible in neurons suggesting that the toxic
event can precede tau filament formation. Furthermore,
we demonstrate that endogenous astrocytes derived from
7 day-old human P301S tau mice lack key molecules that
regulate glutamate homeostasis, and support neuronal
survival and synaptogenesis. Understanding the molecular
events of astrocyte induced dysfunction will lead to a bet-
ter understanding of the disease process, while the result
obtained for TSP-1 may have promising implications for
the development of future treatment strategies for neuro-
degenerative disorders, such as tauopathies.
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Additional file 1: Figure S1. a. Immunofluorescent staining for human
P301S tau (HT7, green) and GFAP (astrocytes, red). Brain secDons (25 μm)
from 9 day (top row) and 5 m (boLom row) P301S mice showing no
overlap. b. The blot shows that P301S tau is not expressed in cultured
astrocytes from 9 day old C57 (C), P301S (PS) or P301L (PL) pups (middle
panel, 2 independent 8-‐day cultures); the right hand two lanes show tau
expression in brain extracts from 5 m C57 and 5 m P301S mice run on
the same blot as negaDve and posiDve controls. Top panel, Ponceau;
boLom panel, blot reprobed for β-actin (without stripping). mw, marker
lane. (PDF 1.47 mb)
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